Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:HCWB

HCW Biologics 8/18/2025 Earnings Report

HCW Biologics logo
$1.06 -0.28 (-20.90%)
Closing price 05/19/2026 04:00 PM Eastern
Extended Trading
$1.02 -0.04 (-3.30%)
As of 05/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCW Biologics EPS Results

Actual EPS
-$6.79
Consensus EPS
$1.80
Beat/Miss
Missed by -$8.59
One Year Ago EPS
N/A

HCW Biologics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$7.00 million
Beat/Miss
Missed by -$6.99 million
YoY Revenue Growth
N/A

HCW Biologics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

HCW Biologics' next earnings date is estimated for Friday, August 7, 2026, based on past reporting schedules.

Conference Call Resources

HCW Biologics Earnings Headlines

Why HCW Biologics Stock Is Falling On Tuesday?
What's going on with HCW Biologics stock Monday?
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.tc pixel
Penny Stocks To Add to Your Watchlist - May 16th
See More HCW Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email.

About HCW Biologics

HCW Biologics (NASDAQ:HCWB), a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

View HCW Biologics Profile